AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
KALA BIO, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001V0GBM6
0.19▲ 0.00 (2.48%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
0.19
Day's Range
0.19 – 0.20
52-Week Range
0.07 – 3.96
Volume
204.5K
Avg Volume
1.7M
Share Statistics
Shares Outstanding
Employees
6
Exchange
XNAS
Listed
2017-07-20
Share count as of August 14, 2026

KALA BIO, Inc. Common Stock (KALA) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about KALA BIO, Inc. Common Stock (KALA)
What is KALA BIO, Inc. Common Stock's Market Cap?
KALA BIO, Inc. Common Stock's Market Cap is $3.7M, based on as-reported figures from SEC (XBRL) filings.
What is KALA BIO, Inc. Common Stock's Revenue (TTM)?
KALA BIO, Inc. Common Stock's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is KALA BIO, Inc. Common Stock's Net Income (TTM)?
KALA BIO, Inc. Common Stock's Net Income (TTM) is -$10.1M, based on as-reported figures from SEC (XBRL) filings.
What is KALA BIO, Inc. Common Stock's EBITDA?
KALA BIO, Inc. Common Stock's EBITDA is -$20.7M, based on as-reported figures from SEC (XBRL) filings.
What is KALA BIO, Inc. Common Stock's Diluted EPS (TTM)?
KALA BIO, Inc. Common Stock's Diluted EPS (TTM) is -0.52, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · KALAAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Costs and expenses:
General and administrative
Research and development
Loss on fair value remeasurement of contingent consideration——
Total costs and expenses
Loss from operations
Other income (expense):
Interest income
Interest expense——
Grant income—
Other income (expense), net
Total other income (expense)
Net loss and comprehensive loss
Net loss per share attributable to common stockholders-basic (in dollar per share)
Net loss per share attributable to common stockholders-diluted (in dollar per share)